Filing Flows › Regenxbio (RGNX) › Q2 2026
Regenxbio (RGNX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Regenxbio (RGNX) reported revenue of $108M for the second quarter 2026 (Q2 2026), +406% from a year earlier and up 17-fold from the quarter before. Operating margin was 27.1%, net earnings $22.7M (21.0% of revenue).
Regenxbio, Q2 2026: revenue $108M (+406% year over year), operating margin 27.1%, net earnings $22.7M, operating cash flow −$62.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $108M | 17× | +406% |
| Operating profit | $29.3M | — | — |
| Net earnings | $22.7M | — | — |
| Operating cash flow | −$62.2M | — | — |
What changed
Revenue was $108.0M in Q2 2026, up 406% year over year and up 1590% from the previous quarter. Abb Vie Development Milestone was the largest line at 93% of revenue. Other Service Revenue added $284K year over year (up 163%), 0% of the total change. Zolgensma Royalties declined 90%.
Operating profit was $29.3M, a 27.1% margin (up 323.3 points year over year). Total costs fell 7% while revenue rose 406%. Net earnings were $22.7M. The effective tax rate was 0.0%.
Operating cash flow was −$62.2M. Non-cash charges added back $3.8M of depreciation and amortization and $9.1M of share-based compensation. Working capital and other items used $97.8M. Capital expenditures of $760K exceeded it, leaving free cash flow of −$63.0M.
Questions
What was Regenxbio's revenue in the second quarter 2026?
Regenxbio (RGNX) reported revenue of $108M for the second quarter 2026 (Q2 2026), +406% from a year earlier and up 17-fold from the quarter before.
Was Regenxbio profitable in the second quarter 2026?
Operating profit was $29.3M (27.1% of revenue) and net earnings $22.7M.
Source: Regenxbio 10-Q on SEC EDGAR.